Original paper

Post-operative complications following dose adaptation of intra-operative electron beam radiation therapy in locally advanced or recurrent rectal cancer

Floor Piqeur, MD[1,2], Heike M.U. Peulen, MD, PhD[1], Jeltsje S. Cnossen, MD, PhD[1], Cathryn C.A. Huibregtse Bimmel-Nagel, MSc[1], Harm J.T. Rutten, MD, PhD[3,4], Jacobus W.A. Burger, MD, PhD[3], An-Sofie E. Verrijssen, MD[1]

[1]Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands, [2]Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands, [3]Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands, [4]GROW School of Oncology and Reproduction, University of Maastricht, Maastricht, The Netherlands

Abstract

Purpose: The benefit of intra-operative radiotherapy (IORT) in the treatment of locally advanced rectal cancer (LARC) or locally recurrent rectal cancer (LRRC) lie in its ability to provide high-dose of radiation to limited at-risk volume, thereby eliminating microscopic disease and decreasing toxicity. A comparative study between high-dose-rate (HDR) brachytherapy, named intra-operative brachytherapy (IOBT), and intra-operative electron radiotherapy (IOERT) was performed showing favorable LRFS after IOBT, possibly due to a higher surface dose that is inherent in IOBT technique. The IOERT technique in Catharina Hospital Eindhoven was adapted to increase the surface dose, aiming to improve local control. Post-operative complications due to an increased radiation dose remain the matter of concern. This retrospective study was performed to compare complication rates before and after adapted IOERT dose.

Material and methods: All patients undergoing surgery with IOERT for LARC or LRRC from September 2019 until July 2023, were considered. Patients selected until August 31, 2021 were included in control cohort ($n = 108$), and those chosen from September 1, 2021 onwards were included in intervention cohort ($n = 92$). Perioperative and (major) post-operative complications were classified retrospectively, during admission, at 30 days, and at 90 days.

Results: In LARC patients, a decrease in post-operative complications was observed ($p = 0.009$). 19% of LARC patients experienced major post-operative surgical complications, i.e., Clavien-Dindo grade 3b-5, regardless of treatment group. No difference in major 90-day complications was noted ($p = 0.142$). In LRRC patients, the use of induction chemotherapy decreased from 78% to 29% ($p < 0.001$), which complicated comparison. However, no difference in major post-operative complications was observed at 30 days ($p = 0.222$) or 90 days ($p = 0.977$) after surgery.

Conclusions: Increased surface dose of IOERT does not seem to lead to an increase in post-operative complications. Further research is needed to evaluate the efficacy of dose adaptation in IOERT to improve local oncological control rates. Routine evaluation of CTCAE scores in follow-up will help uncover possible long-term radiation-induced toxicity.

Purpose

In the field of rectal cancer, the risk of loco-regional recurrence has been reduced by the introduction of total mesorectal excision (TME) surgery that has significantly improved loco-regional control [1-4]. Neoadjuvant (chemo) radiotherapy has further decreased the chance of loco-regional recurrence in patients with locally advanced rectal cancer (LARC) [5-8]. Nevertheless, recurrences still occur and prove difficult to treat. In both primary and locally recurrent rectal cancer (LRRC), a microscopically radical (R0) resection margin has shown to be extremely important in improving local control [4, 7, 9-11].

Intra-operative radiotherapy (IORT) can further improve local control in patients with locally advanced or

recurrent rectal cancer (LARRC), by delivering a high-dose of radiation to a limited at-risk volume, thus reducing excessive toxicity. By applying IORT to the at-risk resection margin, the remaining microscopic disease may be treated intra-operatively [12, 13]. Intra-operative radiotherapy is mainly performed with electrons (IOERT), high-dose-rate (HDR) brachytherapy (IOBT), or low-kV X-rays (orthovoltage).

A recent article compared the results of IOERT vs. IOBT for microscopically irradical (R1) resections in patients with LARRC [14]. An improvement in local recurrence-free survival (LRFS) was observed, favoring IOBT. Not only does this suggest that IORT affects LRFS in general, but the difference in favor of IOBT raises the question of why this might be so. Although many factors may have contributed to this fact, such as different patient populations, larger irradiated volumes, different operating times, and various applicator types, one striking difference is a higher surface dose of IOBT compared with IOERT [15]. Since the surgical resection surface is the site where potential microscopic disease remains, it has been suggested that different surface doses may have contributed strongly to the results. In a second article, the two techniques were compared, and the IOERT technique was adapted to increase the surface dose to approximate that of IOBT (Figure 1) [16]. First, a bolus of tissue equivalent polymethyl methacrylate (PMMA) was added to the IOERT applicator exit to move maximum dose to the tissue surface (Figure 2). The dose was then re-scaled to increase the surface dose to approximate that of IOBT. The prescribed dose (10 Gy) of adjusted dose curve was still at 9 mm, as in the original dose curve of IOERT. In this way, the dosimetric difference between IOERT and IOBT was reduced at the surface. One point of concern, however, is the potential additional toxicity caused by the higher surface dose. As described in a study by Verrijssen

et al., this was not expected, as the published literature on IOBT, which is characterized by a higher surface dose, does not show an increase in toxicity [16]. The present work aimed to confirm this hypothesis.

Material and methods

Patient selection

All patients who underwent surgery in combination with IOERT for LARRC at Catharina Hospital Eindhoven (CHE) from September 1, 2019 to July 31, 2023, were selected. Patients treated until August 31, 2021 were included in the control cohort. Patients treated from September 1, 2021 onwards were included in the intervention group, after the adapted technique was introduced. Patients with a re-recurrence were excluded. Data of LRRC patients were extracted from a prospectively maintained database, and were updated from electronic patient records if necessary. Data of LARC patients were retrieved from medical records. Information recorded included baseline characteristics, neoadjuvant treatment, surgery, outcome, and follow-up. Follow-up was completed until August 29, 2023. The study was approved by the local medical ethics committee (approval No.: nWMO-2022.130).

Neoadjuvant treatment

All patients received neoadjuvant (chemo) radiotherapy. For LARC, treatment regimens consisted of either short course radiotherapy (5 × 5 Gy) or full course chemoradiotherapy (CRT) (25 × 2 Gy), with concomitant capecitabine. Locally recurrent rectal cancer patients were given either full course CRT or chemo re-irradiation (15 × 2 Gy), with concomitant capecitabine. Selected LARRC patients received induction chemotherapy prior to (chemo) radiotherapy, which generally consisted of either 3-4 courses of CAPOX (capecitabine and oxaliplatin) or 4-6 courses of FOLFOX (5-FU, leucovorin, and oxaliplatin).

Surgery was categorized as follows: abdomino-perineal resection (APR), low-anterior resection (LAR), total exenteration (TE, including a resection of the rectum,

Fig. 1. Graph showing current situation for IOERT and IOBT in absolute dose at depth for IOBT (solid line) and IOERT (long dashed line). Short dashed line illustrates the IOERT curve after applying a bolus, but before re-scaling. Dotted line shows the IOERT curve with a bolus and re-scaling to deliver 10 Gy at 9 mm

Fig. 2. Picture of tissue-equivalent polymethyl methacrylate (PMMA) bolus attached to IOERT applicator exit to move maximum dose to tissue surface

bladder, prostate, and vesicles in male patients, or ovaries, vagina, and uterus in female patients), and a tumor resection not otherwise specified (n.o.s.), i.e., tumor resection without formal bowel resection. All resections performed in addition to a formal bowel resection were documented separately (i.e., in the case of a TE, resections of the bladder, prostate, and vesicles were also noted separately).

Intra-operative electron radiotherapy

A preliminary assessment of IOERT indication is performed for all patients undergoing either curative surgery or surgery in a palliative setting, for maximal local control of LARRC. This is done during an expert multidisciplinary tumor board, including at least an oncologic surgeon, medical oncologist, radiation oncologist, and radiologist, where staging at baseline and after neoadjuvant treatment is discussed. Perioperatively, the IOERT indication is re-established by a surgeon and radiation oncologist. In both instances, a clinical suspicion of either narrow or involved resection margins is considered an IOERT indication. Additional frozen sections of excised tissue can be used perioperatively to aid decision-making, but are not required. The IOERT dose and irradiation site are also determined perioperatively, targeting the area at-risk for R1 resection. IOERT is administered using Mobetron 2000 linear accelerator (IntraOp Medical, Sunnyvale California, USA), with energy of either 6, 9, or 12 MeV. Applicators with a diameter of five to ten centimeters can be used, with bevel angles of 0, 30, or 45 degrees. The dose-rate is set at around 10 Gy/min. The IOERT dose previously depended on the depth of tissue considered at-risk for R1 resection, and was prescribed (at depth) at 10 Gy, 12.5 Gy, or 14.4 Gy to 90% isodose surface. From September 1, 2021 onwards, all patients received a dose of 10 Gy at the target depth, which corresponded to a dose between 15.5 Gy and 16.5 Gy at the tissue surface (Figure 1) [16]. The following IOERT variables were reported for each patient: dose at target depth, dose at surface (i.e., at 1 mm tissue depth), and irradiated surface (cm²).

Complications

Follow-up was performed according to the Dutch national guidelines for colorectal cancer [17]. Endpoints included all complications and readmissions within 30 days after surgery as well as all major post-operative complications 90 days after surgery. Analyses were performed separately for LARC and LRRC. Perioperative and post-operative complications were retrospectively classified using Clavien-Dindo classification [18, 19]. The highest Clavien-Dindo grade was noted for each patient up to 30 days after surgery. Major post-operative complications (Clavien-Dindo grade 3b-5) were additionally classified at 90 days post-operatively. From September 1, 2021, adverse events were routinely assessed by a radiation oncologist with common terminology criteria for adverse events, version 5.0 (CTCAE) at 3 and 12 months post-IOERT. These data were used to assess any long-term post-operative neuropathy. If not available, patient records were reviewed for evidence of peripheral neuropathy. No neuropathy was only classified if it was explicitly stated that no peripheral neuropathy was present.

Statistical analysis

Continuous data were expressed as a median (interquartile range – IQR) or mean (standard deviation – SD), as appropriate. Categorical data were presented as absolute numbers with percentages. Comparisons of continuous data were performed using independent t test, Wilcoxon sign rank test, and Mann-Whitney U test, as appropriate. Comparisons of categorical data were performed with chi-square test and Fisher-exact test, as appropriate. Two-sided p-values of < 0.05 were considered statistically significant. Statistical analyses were performed using IBM Statistical Package for the Social Sciences (SPSS) Statistics for Windows, version 29.0 (IBM Corp. Released 2022, Armonk, NY: IBM Corp.)

Results

Locally advanced rectal cancer

Between January 1, 2019 and July 31, 2023, 101 patients underwent surgery, of whom 54 (53%) were treated in the control group, and 47 (47%) in the (dose-escalated) intervention group. There were no significant differences in baseline characteristics, as summarized in Table 1. Surgeries performed were similar among treatment groups (p = 0.248) (Table 2). Additional treatment characteristics of LARRC patients with metastatic disease can be found in Supplementary Material. Overall, patients in the intervention group underwent fewer additional resections than patients in the control group (13% vs. 32%, p = 0.025), and significantly more pelvic sidewall resections were performed in the intervention group (40% vs. 19%, p = 0.015). Of the 54 patients in the control cohort, 34 (63%) received 10 Gy, 9 (17%) received 11.5 Gy, 7 received 12.5 Gy (13%), and 4 received 14.4 Gy (7%), both at surface and at depth. All patients in the intervention group received 10 Gy at depth, but obtained significantly higher IOERT dose at tissue surface: 15.0 Gy (n = 1; 2%), 15.5 Gy (n = 20; 43%), 16 Gy (n = 26; 55%), with a median of 16 Gy (IQR, 15.5-16) vs. 10 Gy (IQR, 10-12) in the historical cohort (p < 0.001). The irradiated surface was similar (p = 0.13).

Table 3 shows comparisons of complications and readmissions for all patients. In LARC patients, the length of stay was shorter in the intervention group (7 days vs. 10 days, p = 0.010). There were significantly fewer 30-day post-operative complications in the intervention group (80% vs. 55%, p = 0.009), but the type of complications did not differ. Importantly, there was no increase in infectious gastrointestinal complications (p = 0.267) or wound complications (p = 0.748). Major post-operative complications were reported in 19% of patients, with no difference between treatment groups (20% vs. 17%, p = 0.761). There was no difference in complications at 90 days post-operatively (11% vs. 23%, p = 0.142), although data were missing in 24% of patients, mainly in the control group (30% vs. 17%).

Table 1. Baseline, tumor, and neoadjuvant treatment characteristics of patients with LARC and LRRC

Characteristic (LARC)		Control (n = 54), n (%)	Intervention (n = 47), n (%)	Total (n = 101), n (%)	p-value
Gender	Male	35 (65)	28 (60)	63 (62)	0.588
	Female	19 (35)	19 (40)	38 (38)	
Age at diagnosis	Mean (SD)	62 (10.1)	60 (11.9)	61 (11.0)	0.180
T stage	T3	23 (43)	13 (28)	36 (36)	0.137
	T4	31 (57)	33 (72)	64 (64)	
N stage	N0	9 (17)	7 (15)	16 (16)	0.844
	N+	45 (83)	39 (85)	84 (84)	
M stage	M0	45 (83)	36 (77)	81 (80)	0.458
	M1	9 (17)	11 (23)	20 (20)	
MRF involved	Yes	44 (90)	39 (89)	83 (89)	0.857
Induction chemotherapy	No	30 (56)	19 (40)	49 (49)	0.129
	Yes	24 (44)	28 (60)	52 (52)	
Neoadjuvant RT	25 × 2 Gy	47 (87)	41 (87)	88 (87)	0.722
	5 × 5 Gy	6 (11)	4 (9)	10 (10)	
	Other	1 (2)	2 (4)	3 (3)	
Interval RT to surgery (weeks)	Median (IQR)	13 (12-15)	14 (12-18)	13 (12-16)	0.134
Characteristic (LRRC)		Control (n = 54), n (%)	Intervention (n = 45), n (%)	Total (n = 99), n (%)	p-value
Gender	Male	37 (69)	32 (71)	69 (70)	0.780
	Female	17 (32)	13 (29)	30 (30)	
Age at diagnosis	Mean (SD)	65 (9)	67 (8.5)	66 (8.8)	0.278
Multifocal recurrence	No	40 (76)	35 (78)	75 (77)	0.788
	Yes	13 (25)	10 (22)	23 (24)	
Induction chemotherapy	No	12 (22)	32 (71)	55 (44)	< 0.001
	Yes	42 (78)	13 (29)	55 (56)	
Neoadjuvant RT	Full course	22 (41)	14 (31)	36 (36)	0.392
	Re-irradiation	31 (57)	30 (67)	61 (62)	
	Other	1 (2)	1 (2)	2 (2)	
Metastases at diagnosis	No	48 (89)	43 (96)	91 (92)	0.286
	Yes	6 (11)	2 (4)	8 (8)	
Interval RT to surgery (weeks)	Median (IQR)	13 (11-14)	13 (11-14)	13 (11-14)	0.673

MRF – mesorectal fascia, RT – radiation therapy. Missing data were excluded from group comparisons; Due to rounding, not all percentages added up to 100%

Locally recurrent rectal cancer

Between January 1, 2019 and July 31, 2023, 99 patients with LRRC underwent surgery, of which 45 (45%) were treated in the intervention group. The baseline characteristics of LRRC are presented in Table 1. The characteristics of the primary tumor characteristics are shown in Supplementary Material. No differences in baseline characteristics were observed. However, patients in the intervention cohort received significantly less induction chemotherapy (78% vs. 29%, $p < 0.001$), but neoadjuvant CRT was similar ($p = 0.392$).

Full details of surgery and IOERT treatments are given in Table 2. Forty-nine percent of patients in the intervention group underwent a TE compared with 19% in the control group ($p = 0.006$). Significantly more bladder (53% vs. 17%, $p < 0.001$) and prostate resections (63% vs. 27%, $p = 0.003$) were performed in the intervention group,

partly due to the higher number of TEs performed. Although the operations were more extensive, there was no difference in the duration of surgery ($p = 0.674$).

Thirty-seven (67%) patients in the control group received 10 Gy IOERT, 6 (11%) received 11.5 Gy, 7 received 12.5 Gy (13%), and 5 received 14.4 Gy (9%), both at the surface and at the specification depth. The dose at the depth was 10 Gy for all patients in the intervention group, but the dose at the surface was significantly higher, i.e., 15.5 Gy ($n = 26$; 58%) and 16 Gy ($n = 19$; 42%), with a median of 15.5 Gy vs. 10 Gy ($p < 0.001$). The irradiated surface was larger in the intervention group (40 cm^2) than in the control group (28 cm^2) ($p = 0.009$). The overview of the applicator diameter and bevel used is presented in Supplementary Material.

Post-operative complications were common but similar, occurring in 74% and 76% of patients, before and

Table 2. Surgical and intra-operative radiation therapy characteristics of patients with locally advanced rectal cancer (LARC) and locally recurrent rectal cancer (LRRC)

Characteristic		LARC				LRRC			
		Control (n = 54), n (%)	Intervention (n = 47), n (%)	Total (n = 101), n (%)	p-value	Control (n = 54), n (%)	Intervention (n = 45), n (%)	Total (n = 99), n (%)	p-value
Surgical procedure	LAR	18 (33)	23 (49)	41 (41)	0.248	9 (17)	3 (7)	12 (12)	0.006
	APR	29 (54)	18 (38)	47 (47)		18 (33)	14 (31)	32 (32)	
	Total exenteration	7 (13)	6 (13)	13 (13)		10 (19)	22 (49)	32 (32)	
	Resection n.o.s.	0 (0)	0 (0)	0 (0)		17 (32)	6 (13)	23 (23)	
Blood loss (l)	Median (IQR)	1.4 (0.8-2.0)	0.9 (0.5-1.6)	1.1 (0.7-1.8)	0.062	2.0 (1.1-2.9)	2.5 (1.4-4.0)	2.2 (1.1-3.5)	0.069
Time surgery (h)	Median (IQR)	4 (3-4)	4 (3-5)	4 (3-5)	0.025	5 (4-6)	5 (4-6)	5 (4-6)	0.674
Additional resection performed	No	37 (69)	41 (87)	78 (77)		10 (19)	3 (7)	13 (13)	0.082
	Yes	17 (32)	6 (13)	23 (23)		44 (82)	42 (93)	86 (87)	
	Bladder	7 (13)	6 (13)	13 (13)	0.990	9 (17)	24 (53)	33 (33)	< 0.001
	Pelvic side wall	10 (19)	19 (40)	29 (29)	0.015	10 (19)	17 (38)	27 (27)	0.032
	Prostate	8 (23)	9 (32)	17 (27)	0.409	10 (27)	20 (63)	30 (44)	0.003
	Vesicles	15 (43)	17 (61)	32 (51)	0.159	18 (49)	22 (69)	40 (58)	0.092
IOERT dose at depth (Gy)	Median (IQR)	10 (10-12)	10 (10-10)	10 (10-10)	< 0.001	10 (10-12)	10 (10-10)	10 (10-13)	< 0.001
IOERT dose at surface (Gy)	Median (IQR)	10 (10-12)	16 (16-16)	14 (10-16)	< 0.001	10 (10-12)	16 (16-16)	13 (10-16)	< 0.001
EQD$_2$ cumulative dose (Gy) (total)	Median (IQR)	N.A.	N.A.	N.A.	N.A.	78 (67-97)	94 (83-113)	94 (73-103)	0.002
EQD$_2$ cumulative dose (Gy) (current tumor)	Median (IQR)	67 (67-71)	83 (83-85)	71 (67-83)	< 0.001	53 (47-67)	65 (63-83)	63 (53-67)	< 0.001
IOERT surface (cm^2)	Median (IQR)	28 (28-40)	40 (28-40)	28 (28-40)	0.130	28 (28-40)	40 (28-40)	40 (28-40)	0.009

LAR – low anterior resection, APR – abdominoperineal resection. Missing data were excluded from group comparisons; Due to rounding, not all percentages added up to 100%; Only men were included in group analysis of prostate and vesicle resections. No significant differences were reported in resections of the ureter, sacrum, lymph nodes, uterus, ovaries, or vagina

Table 3. Group comparison of post-operative complications and readmission rates

Characteristic		LARC				LRRC			
		Control (n = 54), n (%)	Intervention (n = 47), n (%)	Total (n = 101), n (%)	p-value	Control (n = 54), n (%)	Intervention (n = 45), n (%)	Total (n = 99), n (%)	p-value
Admission (days)	Median (IQR)	10 (7-14)	7 (5-12)	9 (7-14)	0.010	11 (8-16)	11 (8-15)	11 (8-16)	0.894
Any post-operative complication (30 d)	Any grade	43 (80)	26 (55)	69 (68)	0.009	40 (74)	34 (76)	74 (75)	0.866
Uro-genital complications	Any grade	13 (24)	11 (23)	24 (24)	0.937	13 (24)	6 (13)	19 (19)	0.177
	Grade 1-2	13	10	23		11	5	16	
	Grade 3a-5	0	1	1		2	1	3	
Cardiopulmonary complications	Any grade	8 (15)	2 (4)	10 (10)	0.100	6 (11)	10 (22)	16 (16)	0.135
	Grade 1-2	7	2	9		5	8	13	
	Grade 3a-5	1	0	1		1	2	3	
Wound complications	Any grade	6 (11)	4 (9)	10 (10)	0.748	4 (7)	5 (11)	9 (9)	0.728
	Grade 1-2	1	0	1		2	4	6	
	Grade 3a-5	5	4	9		2	1	3	
Gastro-intestinal complications	Any grade	24 (44)	19 (40)	43 (43)	0.684	29 (54)	21 (47)	50 (51)	0.486
	Grade 1-2	13	12	25		15	15	30	
	Grade 3a-5	11	7	18		14	6	20	
GI: Ileus/ gastroparesis	Any grade	13 (24)	10 (21)	23 (23)	0.738	19 (35)	14 (31)	33 (33)	0.669
	Grade 1-2	11	8	19		14	12	26	
	Grade 3a-5	2	2	4		5	2	7	
GI: Infectious (including abscess)	Any grade	10 (19)	5 (11)	15 (15)	0.267	14 (26)	10 (22)	24 (24)	0.669
	Grade 1-2	2	2	4		4	5	9	
	Grade 3a-5	8	3	11		10	5	15	
Other complications	Any grade	11 (20)	5 (11)	16 (16)	0.182	16 (30)	15 (33)	31 (31)	0.692
	Grade 1-2	10	4	14		11	8	19	
	Grade 3a-5	1	1	2		5	7	12	
Highest Clavien-Dindo (30 d)	Grade 0-2	38 (70)	36 (77)	74 (73)	0.761	33 (61)	31 (69)	64 (65)	0.624
	Grade 3a	5 (9)	3 (6)	8 (8)		3 (6)	3 (7)	6 (6)	
	Grade 3b-5	11 (20)	8 (17)	19 (19)		18 (33)	11 (24)	29 (29)	
Readmission (30 d)	No	50 (93)	42 (89)	92 (91)	0.730	39 (72)	37 (86)	76 (78)	0.101
	Yes	4 (7)	5 (11)	9 (9)		15 (28)	6 (14)	21 (22)	
Late major complications (31-90 d)	No	34 (90)	30 (77)	64 (83)	0.142	23 (62)	20 (63)	43 (62)	0.977
	Clavien-Dindo grade 3b-5 Yes	4 (11)	9 (23)	13 (17)		14 (38)	12 (38)	26 (38)	

Missing data were excluded from group comparisons; Due to rounding, not all percentages added up to 100%

Table 4. Physician-reported peripheral neuropathy

Characteristic		Control (n = 108), n (%)	Intervention (n = 92), n (%)	Total (n = 200), n (%)	p-value
Physician-reported neuropathy	30 days (n = 170)	16 (15)	10 (11)	26 (15)	0.379
	90 days (n = 141)	14 (17)	16 (29)	30 (21)	0.258
	12 months (n = 83)	4 (8)	9 (28)	13 (16)	0.019

Fig. 3. Physician-reported peripheral neuropathy, relatively displayed. Missing data were excluded from analysis. Peripheral neuropathy was analyzed for all patients to account for low number of events

after dose adjustment, respectively (p = 0.866). Major post-operative complications occurred in 18 patients before (33%) and in 11 patients after (24%) dose adjustment (p = 0.624) at 30 days. There was no difference in the type of complications. Also, no difference was found in major complications at 90 days (p = 0.977), but data was missing in 32% and 22% patients from the control and intervention groups, respectively.

Peripheral neuropathy

Peripheral neuropathy was reported in 26 patients (15%) within 30 days, and in 30 patients (21%) within 90 days of surgery, as shown in Table 4 and Figure 3. An increase in reported neuropathy was observed at 12 months post-operatively in the intervention group (28%) compared with the control group (8%) (p = 0.019), but not at 30 or 90 days post-operatively. Data were missing in 15% at 30 days, in 30% at 90 days, and in 59% of patients at 12 months post-operatively. No CTCAE grade 4 or 5 neuropathy was observed. Operation reports were reviewed to investigate possible effects of surgery. In 12 patients (48%), neuropathy can be explained (in part) by the explicitly mentioned surgical resection of nerves or plexuses. Ten patients reported peripheral neuropathy at baseline that was due to chemotherapy or previous surgery. Peripheral neuropathy over time is shown in Supplementary Material.

Discussion

The current study suggests that increasing the IOERT surface dose in LARRC patients does not lead to an increase in post-operative complications. These results are in line with expectations expressed when the technique adaptation was introduced [16]. In Voogt *et al.* study, significantly more major complications occurred in LRRC patients treated with IOBT than with IOERT [14]. These

complications included pre-sacral abscesses (26%), abdominal wound dehiscence with evisceration (8%), and intra-abdominal abscesses (6%). Several possible explanations were mentioned, such as a larger irradiated area with IOBT and a slower dose fall-off of IOBT, meaning that a larger volume of tissue received a higher dose. Operating times were also generally longer, as more time is required for applicator modulation and treatment planning. Another reason could be the higher surface dose of IOBT, with more heterogeneity within the surface dose and more hotspots. However, in this study, no increase in post-operative complications was observed despite an increase in the surface dose. This may indicate that the increased toxicity was caused by the other reasons mentioned.

In this study, there was a visible trend towards a larger irradiated area in the intervention group. However, the IOERT-irradiated volume was still smaller than that of IOBT. Previous studies have shown IOBT volumes on average 2-3 times larger than IOERT, with an upper limit exceeding 200 cm^2 [14, 20-22]. Therefore, the relatively small irradiated volume in IOERT may explain why no increase in complications was observed. An alternative hypothesis could be that although the surface dose was increased, the dose fall-off was steeper because of the dose build-up within the PMMA bolus (Figure 1). Moreover, the IOERT dose in the historical cohort was scaled up to 14.4 Gy to increase the surface dose; however, owing to the physical properties, this also led to an increased dose beyond one centimeter depth. Therefore, with the PMMA bolus applied, theoretically, the dose at depth was less than that in the historical cohort.

Several factors complicated comparisons in this analysis. Due to the initiation of PelvEx II trial in LRRC, the proportion of patients receiving induction chemotherapy decreased, as induction chemotherapy was the standard of care for LRRC prior to PelvEx II study in the CHE [23].

This may have decreased the perioperative morbidity, concealing the possible increase in toxicity due to IOERT. Although data on toxicity due to pre-operative chemotherapy is lacking in LRRC, RAPIDO trial with LARC patients reported no increase in post-operative complications after 6 cycles of CAPOX [7]. Moreover, in the current study, the proportion of patients treated with induction chemotherapy in LARC showed an increasing trend (44% vs. 60%, $p = 0.129$), in part due to MEND-IT trial investigating the benefit of FOLFOXIRI induction chemotherapy in LARC [24]. Nevertheless, in patients with LARC, no increase in toxicity was observed. Therefore, the confounding effect of induction chemotherapy on perioperative and post-operative complications may be minimal. Prospective data generated from both the trials will provide more insight on induction chemotherapy-related complications [23, 25].

The differences in surgical techniques further complicate the comparison. In patients with LARC, the proportion of LAR vs. APR vs. TE was consistent. In LRRC, resections were significantly more extensive in the intervention cohort, due to an increase in TEs (19% vs. 49%). This increase may be related to a cohort study comparing LRRC management between the Karolinska Institute (KAR) and CHE, revealing more R0 resections at KAR (76% R0 vs. 61%), hypothesized to be due to more TEs (KAR 25% vs. CHE 16%, $p = 0.02$), with no difference in major complications (KAR 32% vs. CHE 30%, $p = 0.742$) [26]. On the one hand, more extensive resections could lead to an increase in complications and length of surgery. On the other hand, a TE is an en bloc resection, whereas operating more conservatively may result in additional partial resections, possibly leading to more tissue-healing complications. Nevertheless, no difference in complications was observed when stratifying for IOERT technique in either LARC or LRRC patients, despite varying operative management, supporting the idea that IOERT dose adaptation did not influence complications.

Peripheral neuropathy is an area of concern. The literature states that 3-23% of patients suffer from peripheral neuropathy due to extensive surgery and radiation within the pelvis [27, 28]. Clinically, there seems to be underreporting of peripheral neuropathy, and it should be expected that this is also true in the current study. Although the data were limited, there was an increase in peripheral neuropathy in the intervention group at 12 months. However, shortly prior to introducing the dose adaptation, a routine evaluation of peripheral neuropathy *via* CTCAE scoring at three months and one year post-operatively was performed. Therefore, it is possible that the increase in peripheral neuropathy is merely due to the improved reporting rather than due to the increased surface dose. Other factors influencing neuropathy are the surgery itself and chemotherapy [29]. As reported, neuropathy may also be explained by the performed surgery in several patients, as damage to the nerves or plexus within the pelvis was specifically mentioned in the surgical report. However, in reality, this percentage may be higher. When combining these factors, drawing conclusions, even on the extent of peripheral neuropathy as well as the difference in neuropathy between IOERT techniques, is challenging. Standardized CTCAE scoring of peripheral neuropathies will help improving our understanding of this potentially invalidating toxicity following IOERT. Neuropathy should remain an area of caution, as it can lead to severe decrease in quality of life [29-31].

One potential drawback of the new technique is the compromised view of target volume due to the PMMA bolus attached at the applicator exit. Adequate inspection of the at-risk volume and surrounding healthy tissue is necessary, with thorough multidisciplinary communication to deliver IOERT accurately and safely. Target volume reproducibility is also challenging, and may impede future treatment planning or understanding of IOERT-related complications. Intra-operative navigation may be able to provide a solution by facilitating pre-operative planning on MRI, intra-operative target volume definition, and post-operative dose reconstruction [32-35].

Ultimately, the goal is to improve LRFS. In Voogt *et al.* study, a significantly higher LRFS was reported after IOBT versus IOERT [14]. There are many differences between IOERT and IOBT that may have influenced these results, such as larger irradiated volumes or flexible applicator in IOBT, allowing for closer coverage of the at-risk area [16]. However, the fact remains that the at-risk area is generally at the tissue surface, at the resection margin. Therefore, it was hypothesized that the higher surface dose for IOBT could have contributed largely to these results. Several papers, including that of Appelt *et al.*, indicate a dose-response relationship for tumor regression in rectal cancer [36]. A higher surface dose could translate to a more effective eradication of the remaining microscopic disease. A longer follow-up is needed to evaluate oncological outcomes.

This study has several limitations. Due to the recent introduction of the new technique, and the fact that patients are often referred to their own hospital after surgery, follow-up is often short, limiting conclusions. As follow-up data were mainly missing in the control group, there was a risk of bias and underreporting of complications in the control group; although there is no reason to suspect that the missing data would significantly influence the results. The introduction of the PelvEx II trial and the shift in surgical approach have both caused a significant difference in the characteristics of patients with LRRC. Nevertheless, it is unlikely that a clinically relevant, severe increase in toxicity due to IOERT dose adaptation would be missed because of the mentioned biases.

Although some conclusions can be drawn regarding safety of dose adaptation, no conclusions can be drawn regarding oncological effects. A longer follow-up period in a larger cohort is necessary. Additionally, a larger cohort will be needed to draw conclusions on more subtle complications, such as peripheral neuropathy that can be detrimental to quality of life, but are notoriously difficult to evaluate retrospectively. Standardized CTCAE scores during follow-up will facilitate future toxicity comparisons. Forthcoming work will also consist of analyses of oncological outcomes, especially of (in-field) LRFS, providing more information on the efficacy of dose adaption.

Conclusions

An increased surface dose of IOERT did not appear to increase post-operative complications. Further research is needed to evaluate the efficacy of dose adaptation of IOERT in improving the local oncological control rates. Routine evaluation of CTCAE scores during follow-up will help uncover possible long-term radiation-induced toxicities.

Funding

Disclosure

The authors report no conflict of interest.

Supplementary material is available on journal's website.

References

1. Detering R, Karthaus EG, Borstlap WAA et al. Treatment and survival of locally recurrent rectal cancer: A cross-sectional population study 15 years after the Dutch TME trial. *Eur J Surg Oncol* 2019; 45: 2059-2069.
2. van Gijn W, M Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol* 2011; 12: 575-582.
3. Gao Z, Gu J. Surgical treatment of locally recurrent rectal cancer: a narrative review. *Ann Transl Med* 2021; 9: 1026.
4. Tanis PJ, Doeksen A, Van Lanschot JJB. Intentionally curative treatment of locally recurrent rectal cancer: A systematic review. *Can J Surg* 2013; 56: 135-144.
5. Conroy T, Bosset JF, Etienne PL et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2021; 22: 702-715.
6. Giunta EF, Bregni G, Pretta A et al. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials. *Cancer Treat Rev* 2021; 96: 102177.
7. Hospers G, Bahadoer RR, Dijkstra EA et al. Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial. *J Clin Oncol* 2020; 38 (15 Suppl).
8. Fokas E, Schlenska-Lange A, Polat B et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: Long-term results of the CAO/ARO/AIO-12 randomized clinical trial. *JAMA Oncol* 2022; 8: e215445.
9. Hagemans JAW, van Rees JM, Alberda WJ et al. Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. *Eur J Surg Oncol* 2020; 46: 448-454.
10. Collaborative P. Contemporary management of locally advanced and recurrent rectal cancer: Views from the PelvEx Collaborative. *Cancers (Basel)* 2022; 14: 1161.
11. Wu H, Fan C, Fang C, Huang L et al. Preoperative short-course radiotherapy followed by consolidation chemotherapy for treatment with locally advanced rectal cancer: a meta-analysis. *Radiat Oncol* 2022; 17: 14.
12. Calvo FA, Sole CV, Rutten HJ et al. ESTRO/ACROP IORT recommendations for intraoperative radiation therapy in locally recurrent rectal cancer. *Clin Transl Radiat Oncol* 2020; 24: 41-48.
13. Calvo FA, Sole CV, Rutten HJ et al. ESTRO/ACROP IORT recommendations for intraoperative radiation therapy in primary locally advanced rectal cancer. *Clin Transl Radiat Oncol* 2020; 25: 29-36.
14. Voogt ELK, van Rees JM, Hagemans JAW et al. Intraoperative electron beam radiation therapy (IOERT) versus high-dose-rate intraoperative brachytherapy (HDR-IORT) in patients with an R1 resection for locally advanced or locally recurrent rectal cancer. *Int J Radiat Oncol Biol Phys* 2021; 110: 1032-1043.
15. Nag S, Willett CG, Gunderson LL et al. IORT with electron-beam, high-dose-rate brachytherapy or low-KV/electronic brachytherapy: Methodological comparisons. Intraoperative Irradiation 2011; Corpus ID: 137803831.
16. Verrijssen ASE, Dries WJF, Cnossen JS et al. Narrowing the difference in dose delivery for IOERT and IOBT for locally advanced and locally recurrent rectal cancer. *J Contemp Brachytherapy* 2022; 14: 370-378.
17. Federation of Medical Specialists. Richtlijnendatabase. Dutch National Guidelines for Colorectal Cancer. 2020.
18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; 240: 205-213.
19. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017.
20. Terezakis S, Morikawa L, Wu A et al. Long-term survival after high-dose-rate brachytherapy for locally advanced or recurrent colorectal adenocarcinoma. *Ann Surg Oncol* 2015; 22: 2168-2178.
21. Kolkman-Deurloo IKK, Nuyttens JJ, Hanssens PEJ et al. Intraoperative HDR brachytherapy for rectal cancer using a flexible intraoperative template: Standard plans versus individual planning. *Radiother Oncol* 2004; 70: 75-79.
22. Nuyttens JJ, Kolkman-Deurloo IKK, Vermaas M et al. High-dose-rate intraoperative radiotherapy for close or positive margins in patients with locally advanced or recurrent rectal cancer. *Int J Radiat Oncol Biol Phys* 2004; 58: 106-112.
23. Voogt E, Burger P. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: the PelvEx II study. *Eur J Surg Oncol* 2021; 47: e22-23.
24. van den Berg K, Schaap DP, Voogt ELK et al. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT). *BMC Cancer* 2022; 22: 957.
25. Denost Q, Frison E, Salut C et al. A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer – GRECCAR 15 trial protocol. *Colorectal Dis* 2021; 23: 1909-1918.
26. Nordkamp S, Voogt ELK, van Zoggel DMGI et al. Locally recurrent rectal cancer: Oncological outcomes with different treatment strategies in two tertiary referral units. *Br J Surg* 2022; 109: 623-631.
27. Haddock MG. Irradiation of very locally advanced and recurrent rectal cancer. *Semin Radiat Oncol* 2016; 26: 226-235.

28. Haddock MG. Intraoperative radiation therapy for colon and rectal cancers: A clinical review. *Radiat Oncol* 2017; 12: 11.

29. Teng C, Cohen J, Egger S et al. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer. *Support Care Cancer* 2022; 30: 33-47.

30. Mols F, Beijers T, Vreugdenhil G et al. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. *Support Care Cancer* 2014; 22: 2261-2269.

31. Mannaerts GHH, Rutten HJT, Martijn H et al. Effects on functional outcome after IORT-containing multimodality treatment for locally advanced primary and locally recurrent rectal cancer. *Int J Radiat Oncol Biol Phys* 2002; 54: 1082-1088.

32. Kok END, van Veen R, Groen HC et al. Association of image-guided navigation with complete resection rate in patients with locally advanced primary and recurrent rectal cancer: A nonrandomized controlled trial. *JAMA Netw Open* 2020; 3: e208522.

33. Nijkamp J, Kuhlmann KFD, Ivashchenko O et al. Prospective study on image-guided navigation surgery for pelvic malignancies. *J Surg Oncol* 2019; 119: 510-517.

34. Groen HC, den Hartog AG, Heerink WJ et al. Use of image-guided surgical navigation during resection of locally recurrent rectal cancer. *Life (Basel)* 2022; 12: 645.

35. Karius A, Karolczak M, Strnad V et al. Technical evaluation of the cone-beam computed tomography imaging performance of a novel, mobile, gantry-based X-ray system for brachytherapy. *J Appl Clin Med Phys* 2022; 23: e13501.

36. Appelt AL, Ploen J, Vogelius IR et al. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. *Int J Radiat Oncol Biol Phys* 2013; 85: 74-80.